Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:CGTX NASDAQ:CUE NASDAQ:CYPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.09-0.6%$1.24$0.88▼$5.48$27.48M0.4277,274 shs18,539 shsCGTXCognition Therapeutics$1.21+3.9%$1.06$0.22▼$3.83$107.67M1.811.05 million shs267,298 shsCUECue Biopharma$36.35+1.7%$254.22$4.97▼$41.42$117.58M2.37531,034 shs63,988 shsCYPHCypherpunk Technologies$1.20+13.0%$0.78$0.23▼$3.70$116.98M-0.092.81 million shs1.73 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma0.00%+6.80%-24.14%-36.78%-13.39%CGTXCognition Therapeutics-5.69%-7.94%+41.91%+9.43%+227.04%CUECue Biopharma+5.15%+142.40%-78.91%-87.60%-94.76%CYPHCypherpunk Technologies-6.19%+19.22%+45.36%+52.74%+209.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.09-0.6%$1.24$0.88▼$5.48$27.48M0.4277,274 shs18,539 shsCGTXCognition Therapeutics$1.21+3.9%$1.06$0.22▼$3.83$107.67M1.811.05 million shs267,298 shsCUECue Biopharma$36.35+1.7%$254.22$4.97▼$41.42$117.58M2.37531,034 shs63,988 shsCYPHCypherpunk Technologies$1.20+13.0%$0.78$0.23▼$3.70$116.98M-0.092.81 million shs1.73 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma0.00%+6.80%-24.14%-36.78%-13.39%CGTXCognition Therapeutics-5.69%-7.94%+41.91%+9.43%+227.04%CUECue Biopharma+5.15%+142.40%-78.91%-87.60%-94.76%CYPHCypherpunk Technologies-6.19%+19.22%+45.36%+52.74%+209.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/ACGTXCognition Therapeutics 2.50Moderate Buy$3.33176.63% UpsideCUECue Biopharma 1.00SellN/AN/ACYPHCypherpunk Technologies 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ABVC, CYPH, CUE, and CGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)3/27/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026CGTXCognition Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharmaN/AN/AN/AN/A$0.52 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/ACUECue Biopharma$27.47M4.29N/AN/A$10.08 per share3.61CYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-65.11%-40.13%5/19/2026 (Estimated)CGTXCognition Therapeutics-$23.49M-$0.33N/AN/AN/AN/A-104.27%-69.64%N/ACUECue Biopharma-$26.60M-$9.61N/AN/AN/A-96.85%-165.19%-77.77%N/ACYPHCypherpunk Technologies$4.82M$0.0717.11N/AN/AN/A-99.76%-79.44%5/18/2026 (Estimated)Latest ABVC, CYPH, CUE, and CGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CYPHCypherpunk Technologies-$0.0406N/AN/AN/AN/AN/A5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/A3/3/2026Q4 2025ABVCABVC BioPharmaN/A-$0.11N/A-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.410.41CGTXCognition TherapeuticsN/A3.453.45CUECue BiopharmaN/A2.742.74CYPHCypherpunk TechnologiesN/A35.5635.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%CGTXCognition Therapeutics43.35%CUECue Biopharma35.04%CYPHCypherpunk Technologies30.46%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%CGTXCognition Therapeutics14.40%CUECue Biopharma1.82%CYPHCypherpunk Technologies4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3025.44 million20.61 millionNot OptionableCGTXCognition Therapeutics2089.35 million76.49 millionNot OptionableCUECue Biopharma603.24 million3.18 millionOptionableCYPHCypherpunk Technologies4097.68 million93.48 millionOptionableABVC, CYPH, CUE, and CGTX HeadlinesRecent News About These CompaniesCypherpunk Technologies (NASDAQ:CYPH) Trading Down 6.1% - What's Next?April 29, 2026 | marketbeat.comCypherpunk Increases its Zcash Stake, Launches New Website and Investor DashboardApril 15, 2026 | prnewswire.comCypherpunk Technologies Announces Planned Board Leadership TransitionsApril 12, 2026 | theglobeandmail.comCypherpunk Technologies (NASDAQ:CYPH) Stock, Option ChainApril 10, 2026 | benzinga.comCypherpunk Technologies (NASDAQ:CYPH) Trading 10.7% Higher - Here's What HappenedApril 8, 2026 | marketbeat.comCypherpunk Technologies Rocked by Major Insider Stock SaleMarch 30, 2026 | tipranks.comCypherpunk Reports Full Year 2025 Financial ResultsMarch 16, 2026 | prnewswire.comMajor VCs Back Zcash Developers With $25 Million After ECC SplitMarch 10, 2026 | bitcoinist.comZcash devs raise $25M from major VCs months after ECC splitMarch 9, 2026 | cointelegraph.comCypherpunk Technologies Receives Nasdaq Minimum Bid Price NoticeMarch 9, 2026 | tipranks.comCypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)March 9, 2026 | prnewswire.comZEC’s Historic Rally and Collapse: What Drove the $7 Billion WipeoutMarch 8, 2026 | blockonomi.comCypherpunk Adds Arjun Khemani as Strategic AdvisorJanuary 22, 2026 | prnewswire.comCypherpunk Technologies restructures CoinXit equity compensation agreementDecember 30, 2025 | tipranks.comCypherpunk Technologies Expands Zcash Holdings in Major PurchaseDecember 30, 2025 | tipranks.comJosh Swihart, ECC CEO, Joins Cypherpunk as Strategic AdvisorDecember 19, 2025 | prnewswire.comWhy Cypherpunk Technologies Inc.’s (CYPH) Stock Is Down 5.21%December 16, 2025 | aaii.comAZcash gains 12% amid rising interest in ZEC treasury Cypherpunk TechnologiesDecember 11, 2025 | fxstreet.comSurveillance is a "Dangerous Experiment" - Zcash Founder Zooko Wilcox on Why Privacy is Actually the Historical NormDecember 10, 2025 | finance.yahoo.comWhy Zcash Could Be Vulnerable To A 50% BreakdownNovember 22, 2025 | newsbtc.comCypherpunk Technologies Modifies Warrant Agreement with WinklevossNovember 20, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, CYPH, CUE, and CGTX Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.09 -0.01 (-0.64%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Cognition Therapeutics NASDAQ:CGTX$1.20 +0.05 (+3.88%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Cue Biopharma NASDAQ:CUE$36.35 +0.62 (+1.74%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Cypherpunk Technologies NASDAQ:CYPH$1.20 +0.14 (+12.98%) As of 10:52 AM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
